10-Q

U.S. SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2023

☐ TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE EXCHANGE ACT

For the Transition Period from              to

Commission file number 1-13463

BIO-KEY INTERNATIONAL, INC.

(Exact Name of registrant as specified in its charter)

Delaware	41-1741861
(State or Other Jurisdiction of Incorporation of Organization)	(IRS Employer Identification Number)

3349 HIGHWAY 138, BUILDING A, SUITE E, WALL, NJ  07719

(Address of Principal Executive Offices)

(732) 359-1100

(Registrant’s telephone number, including area code)

Securities registered pursuance to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of each exchange on which registered
Common Stock, par value $0.0001 per share	BKYI	Nasdaq Capital Market

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐	Accelerated filer ☐
Non-accelerated filer ☒	Smaller Reporting Company ☒
	Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined by rule 12b-2 of the Exchange Act) Yes ☐ No ☒

Number of shares of Common Stock, $.0001 par value per share, outstanding as of June 8, 2023 was 9,234,833.

1

BIO-KEY INTERNATIONAL, INC.

INDEX 

PART I. FINANCIAL INFORMATION
Item 1 — Financial Statements:
Condensed Consolidated Balance Sheets as of March 31, 2023 (unaudited) and December 31, 2022	3
Condensed Consolidated Statements of Operations and Comprehensive Loss for the three months ended March 31, 2023 and 2022 (unaudited)	4
Condensed Consolidated Statements of Stockholders’ Equity for the three months ended March 31, 2023 and 2022 (unaudited)	5
Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2023 and 2022 (unaudited)	7
Notes to Condensed Consolidated Financial Statements	9
Item 2 — Management’s Discussion and Analysis of Financial Condition and Results of Operations.	17
Item 4 — Controls and Procedures.	22
PART II. OTHER INFORMATION
Item 6 — Exhibits.	22
Signatures	23

2

PART I — FINANCIAL INFORMATION

BIO-key International, Inc. and Subsidiaries

CONDENSED CONSOLIDATED BALANCE SHEETS

	March 31, 2023			December 31, 2022
	(Unaudited)
ASSETS
Cash and cash equivalents	$	722,335		$	2,635,522
Accounts receivable, net		3,362,203			1,522,784
Due from factor		82,500			49,500
Inventory, net of reserve		4,427,815			4,434,369
Prepaid expenses and other		341,231			342,706
Total current assets		8,936,084			8,984,881
Equipment and leasehold improvements, net		94,170			107,413
Capitalized contract costs, net		254,279			283,069
Deposits and other assets		8,712			8,712
Operating lease right-of-use assets		131,223			197,355
Intangible assets, net		1,681,589			1,762,825
Total non-current assets		2,169,973			2,359,374
TOTAL ASSETS	$	11,106,057		$	11,344,255
LIABILITIES
Accounts payable	$	1,210,070		$	1,108,279
Accrued liabilities		876,287			1,009,123
Convertible note payable		2,454,212			2,596,203
Government loan – BBVA Bank – current portion		134,899			120,000
Deferred revenue – current		653,338			462,418
Operating lease liabilities, current portion		96,584			159,665
Total current liabilities		5,425,390			5,455,688
Deferred revenue – net of current portion		39,969			52,134
Deferred tax liability		172,997			170,281
Government loan – BBVA Bank – net of current portion		277,580			326,767
Operating lease liabilities, net of current portion		33,366			37,829
Total non-current liabilities		523,912			587,011
TOTAL LIABILITIES		5,949,302			6,042,699
Commitments and Contingencies (Note 7)
STOCKHOLDERS’ EQUITY
Common stock — authorized, 170,000,000 shares; issued and outstanding; 9,226,058 and 9,190,504 of $.0001 par value at March 31, 2023 and December 31, 2022, respectively		922			919
Additional paid-in capital		122,099,984			122,028,612
Accumulated other comprehensive income		(170,456	)		(242,602	)
Accumulated deficit		(116,773,695	)		(116,485,373	)
TOTAL STOCKHOLDERS’ EQUITY		5,156,755			5,301,556
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$	11,106,057		$	11,344,255

The accompanying notes to the condensed consolidated financial statements are an integral part of these statements.

3

BIO-key International, Inc. and Subsidiaries
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(Unaudited)

	Three months ended March 31,
	2023			2022
Revenues
Services	$	532,522		$	395,804
License fees		2,478,556			1,460,183
Hardware		72,689			85,184
Total revenues		3,083,767			1,941,171
Costs and other expenses
Cost of services		154,801			210,913
Cost of license fees		620,881			73,230
Cost of hardware		44,592			53,298
Total costs and other expenses		820,274			337,441
Gross Profit		2,263,493			1,603,730
Operating expenses
Selling, general and administrative		1,931,732			1,797,998
Research, development and engineering		690,159			805,266
Total operating expenses		2,621,891			2,603,264
Operating loss		(358,398	)		(999,534	)
Other income (expense)
Interest income		4			131
Loss on foreign currency transaction		(15,000	)		-
Change in fair value of convertible note		141,991			-
Interest expense		(56,919	)		-
Total other income (expense)		70,076			131
Net loss	$	(288,322	)	$	(999,403	)
Comprehensive loss:
Net loss	$	(288,322	)	$	(999,403	)
Other comprehensive income – Foreign currency translation adjustment		72,146			55,802
Comprehensive loss	$	(216,176	)	$	(943,601	)
Basic and Diluted Loss per Common Share	$	(0.03	)	$	(0.13	)
Weighted Average Shares Outstanding:
Basic and Diluted		8,944,485			7,885,008

The accompanying notes to the condensed consolidated financial statements are an integral part of these statements.

4

BIO-key International, Inc. and Subsidiaries

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(Unaudited)

										Accumulated
							Additional			Other
	Common Stock						Paid-in			Comprehensive			Accumulated
	Shares			Amount			Capital			Income			Deficit			Total
Balance as of January 1, 2023		9,190,504		$	919		$	122,028,612		$	(242,602	)	$	(116,485,373	)	$	5,301,556
Issuance of common stock for directors’ fees		15,388			1			12,001			-			-			12,002
Issuance of common stock to employees		40,000			4			-			-			-			4
Restricted stock forfeited		(19,834	)		(2	)		(3,103	)		-			-			(3,105	)
Foreign currency translation adjustment											72,146			-			72,146
Share-based compensation		-			-			62,474			-			-			62,474
Net loss		-			-			-			-			(288,322	)		(288,322	)
Balance as of March 31, 2023		9,226,058		$	922		$	122,099,984		$	(170,456	)	$	(116,773,695	)	$	5,156,755

The accompanying notes to the condensed consolidated financial statements are an integral part of these statements.

5

BIO-key International, Inc. and Subsidiaries

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (Continued)

(Unaudited)

	Common Stock				Additional Paid-in			Accumulated Other Comprehensive		Accumulated
	Shares		Amount		Capital			Income		Deficit			Total
Balance as of January 1, 2022		7,853,759	$	786	$	120,190,139		$	-	$	(104,575,470	)	$	15,615,455
Issuance of common stock for directors’ fees		9,382		1		22,019			-		-			22,020
Issuance of common stock pursuant to Swivel purchase agreement		269,060		27		599,977			-		-			600,004
Issuance of restricted common stock to employees and directors		274,250		27		(27	)		-		-			-
Foreign currency translation adjustment									55,802		-			55,802
Share-based compensation		-		-		87,677			-		-			87,677
Net loss		-		-		-			-		(999,403	)		(999,403	)
Balance as of March 31, 2022		8,406,451	$	841	$	122,099,785		$	55,802	$	(105,574,873	)	$	15,381,555

The accompanying notes to the condensed consolidated financial statements are an integral part of these statements.

6

BIO-key International, Inc. and Subsidiaries
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)

	Three Months Ended March 31,
	2023			2022
CASH FLOW FROM OPERATING ACTIVITIES:
Net loss	$	(288,322	)	$	(999,403	)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation		13,242			11,220
Amortization of intangible assets		81,237			54,231
Change in fair value of convertible note		(141,991	)		-
Amortization of capitalized contract costs		37,529			35,658
Amortization of operating leases right-of-use assets		66,132			51,587
Stock based directors’ fees		12,002			22,020
Share based compensation for employees and consultants		59,373			87,677
Bad debts		-			25,111
Change in assets and liabilities:
Accounts receivable		(1,798,881	)		(904,930	)
Due from factor		(33,000	)		(2,350	)
Capitalized contract costs		(8,739	)		(66,435	)
Inventory		6,554			(15,812	)
Resalable software license rights		-			2,505
Prepaid expenses and other		2,219			(124,616	)
Accounts payable		88,040			175,341
Accrued liabilities		(135,417	)		45,669
Deferred revenue		178,755			220,874
Operating lease liabilities		(67,544	)		(52,722	)
Net cash used in operating activities		(1,928,811	)		(1,434,375	)
CASH FLOW FROM INVESTING ACTIVITIES:
Purchase of Swivel Secure, net of cash acquired of $729,905		-			(543,578	)
Receipt of cash from note receivable		-			3,000
Capital expenditures		-			(4,459	)
Net cash used in investing activities		-			(545,037	)
CASH FLOW FROM FINANCING ACTIVITIES:
Repayment of government loan		(34,289	)		-
Net cash used in financing activities		(34,289	)		-
Effect of exchange rate changes		49,913			26,487
NET DECREASE IN CASH AND CASH EQUIVALENTS		(1,913,187	)		(1,952,925	)
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD		2,635,522			7,754,046
CASH AND CASH EQUIVALENTS, END OF PERIOD	$	722,335		$	5,801,121

The accompanying notes to the condensed consolidated financial statements are an integral part of these statements.

7

BIO-key International, Inc. and Subsidiaries
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)

SUPPLEMENTARY DISCLOSURES OF CASH FLOW INFORMATION

	Three Months Ended March 31,
	2023		2022
Cash paid for:
Interest	$	56,919	$	-
Noncash Investing and financing activities
Accounts receivable acquired from Swivel Secure	$	—	$	702,886
Equipment acquired from Swivel Secure	$	—	$	65,640
Other assets acquired from Swivel Secure	$	—	$	20,708
Estimated intangible assets acquired from Swivel Secure	$	—	$	1,379,589
Estimated goodwill resulting from the acquisition from Swivel Secure	$	—	$	450,643
Accounts payable and accrued expenses acquired from Swivel Secure	$	—	$	431,884
Government loan acquired from Swivel Secure	$	—	$	544,000
Common stock issued for acquisition of Swivel Secure	$	—	$	600,004

The accompanying notes to the condensed consolidated financial statements are an integral part of these statements.

8

BIO-KEY International Inc., and Subsidiaries 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 

March 31, 2023 (Unaudited)

1. NATURE OF BUSINESS AND BASIS OF PRESENTATION

Nature of Business

The Company, founded in 1993, develops and markets proprietary fingerprint identification biometric technology and software solutions enterprise-ready identity access management solutions to commercial, government and education customers throughout the United States and internationally. The Company was a pioneer in developing automated, finger identification technology that supplements or compliments other methods of identification and verification, such as personal inspection identification, passwords, tokens, smart cards, ID cards, PKI, credit cards, passports, driver’s licenses, OTP or other form of possession or knowledge-based credentialing. Additionally, advanced BIO-key® technology has been, and is, used to improve both the accuracy and speed of competing finger-based biometrics.

Basis of Presentation

The accompanying unaudited interim condensed consolidated financial statements include the accounts of BIO-key International, Inc. and its wholly-owned subsidiaries (collectively, the “Company” or “BIO-key”) and are stated in conformity with accounting principles generally accepted in the United States of America (“GAAP”), pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). The operating results for interim periods are not necessarily indicative of results that may be expected for any other interim period or for the full year. Pursuant to such rules and regulations, certain financial information and footnote disclosures normally included in the financial statements have been condensed or omitted. Intercompany accounts and transactions have been eliminated in consolidation.

In the opinion of management, the accompanying unaudited interim consolidated financial statements contain all necessary adjustments, consisting only of those of a recurring nature, and disclosures to present fairly the Company’s financial position and the results of its operations and cash flows for the periods presented. The balance sheet at December 31, 2022 was derived from the audited financial statements, but does not include all of the disclosures required by GAAP. These unaudited interim condensed consolidated financial statements should be read in conjunction with the financial statements and the related notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the SEC on June 1, 2023.

Foreign Currencies

The Company accounts for foreign currency transactions pursuant to ASC 830, Foreign Currency Matters ("ASC 830”). The functional currency of the Company is the U.S. dollar, which is the currency of the primary economic environment in which it operates. In accordance with ASC 830, all assets and liabilities are translated into U. S. dollars using the current exchange rate at the end of each fiscal period. Revenues and expenses are translated using the average exchange rates prevailing throughout the respective periods. All transaction gains and losses from the measurement of monetary balance sheet items denominated in Euros are reflected in the statement of operations as appropriate. Translation adjustments are included in accumulated other comprehensive income (loss).

9

Recently Issued Accounting Pronouncements

Effective January 1, 2023, the Company adopted ASU 2016-13, Financial Instruments-Credit Losses (Topic 326), referred to herein as ASU 2016-13, which significantly changes how entities will account for credit losses for most financial assets and certain other instruments that are not measured at fair value through net income. ASU 2016-13 replaces the existing incurred loss model with an expected credit loss model that requires entities to estimate an expected lifetime credit loss on most financial assets and certain other instruments. Under ASU 2016-13 credit impairment is recognized as an allowance for credit losses, rather than as a direct write-down of the amortized cost basis of a financial asset. The impairment allowance is a valuation account deducted from the amortized cost basis of financial assets to present the net amount expected to be collected on the financial asset. Once the new pronouncement is adopted by the Company, the allowance for credit losses must be adjusted for management’s current estimate at each reporting date. The new guidance provides no threshold for recognition of impairment allowance. Therefore, entities must also measure expected credit losses on assets that have a low risk of loss. For instance, trade receivables that are either current or not yet due may not require an allowance reserve under currently generally accepted accounting principles, but under the new standard, the Company will have to estimate an allowance for expected credit losses on trade receivables under ASU 2016-13. The adoption of ASU 2016-13 did not have a material effect on the consolidated financial statements of the Company. 

In August 2020, the Financial Accounting Standards Board issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40) (“ASU 2020-06”) to simplify accounting for certain financial instruments. ASU 2020-06 eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity’s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity’s own equity. ASU 2020-06 amends the diluted earnings per share guidance, including the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective for the Company on January 1, 2024 and should be applied on a full or modified retrospective basis. The Company is currently assessing the impact ASU 2020-06 will have on its consolidated financial statements.

Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying consolidated financial statements.

2. GOING CONCERN

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP"), which contemplate continuation of the Company as a going concern, and assumes continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company has suffered substantial net losses and negative cash flows from operations in recent years and is dependent on debt and equity financing to fund its operations all of which raise substantial doubt about the Company’s ability to continue as a going concern. Recoverability of a major portion of the recorded asset amounts shown in the accompanying balance sheet is dependent upon the Company’s ability to increase its revenue and meet its financing requirements on a continuing basis and become profitable in its future operations. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence.

As of the date of this report, the Company does not have enough cash for twelve months of operations. The history of significant losses, the negative cash flow from operations, the limited cash resources on hand and the dependence by the Company on its ability to obtain additional financing to fund its operations after the current cash resources are exhausted raises substantial doubt about the Company's ability to continue as a going concern. The Company has lowered its expenses through decreasing spending in marketing and research and development. In addition, the Company has purchased inventory for projects in Nigeria, which have been delayed in deployment, and is, therefore, looking into other markets and opportunities to sell or return the product to generate additional cash.

3. REVENUE FROM CONTRACTS WITH CUSTOMERS

Disaggregation of Revenue

The following table summarizes revenue from contracts with customers for the three-month period:

	North America		Africa		EMESA*		Asia		March 31, 2023
License fees	$	408,530	$	552,630	$	1,446,746	$	70,650	$	2,478,556
Hardware		24,781		-		47,008		900		72,689
Services		263,858		23,787		239,927		4,950		532,522
Total Revenues	$	697,169	$	576,417	$	1,733,681	$	76,500	$	3,083,767

	North America		Africa		EMESA*		Asia		March 31, 2022
License fees	$	473,070	$	517,161	$	390,277	$	79,675	$	1,460,183
Hardware		71,900		12,033		1,251		-		85,184
Services		355,632		15,275		24,844		53		395,804
Total Revenues	$	900,602	$	544,469	$	416,372	$	79,728	$	1,941,171

*EMESA – Europe, Middle East, South America

10

Deferred Revenue 

Deferred revenue includes customer advances and amounts that have been paid by customer for which the contractual maintenance terms have not yet occurred. The majority of these amounts are related to maintenance contracts for which the revenue is recognized ratably over the applicable term, which generally is 12-60 months. Contracts greater than 12 months are segregated as long term deferred revenue. Maintenance contracts include provisions for unspecified when-and-if available product updates and customer telephone support services. At March 31, 2023 and December 31, 2022, amounts in deferred revenue were approximately $693,000 and $515,000, respectively. Revenue recognized during the three months ended March 31, 2023 and 2022 from amounts included in deferred revenue at the beginning of the period was approximately $223,000 and $234,000, respectively. The Company did not recognize any revenue from performance obligations satisfied in prior periods.

4. ACCOUNTS RECEIVABLE

Accounts receivable are carried at original amount less an estimate made for credit losses based on a review of all outstanding amounts on a monthly basis. Management determines the allowance for credit losses by regularly evaluating individual customer receivables and considering a customer’s financial condition, credit history, current economic conditions and other relevant factors, including specific reserves for certain accounts. Accounts receivable are written off when deemed uncollectible.

Accounts receivable at March 31, 2023 and December 31, 2022 consisted of the following:

	March 31,			December 31,
	2023			2022
Accounts receivable	$	3,985,988		$	2,096,569
Allowance for credit losses		(623,785	)		(573,785	)
Accounts receivable, net of allowance for credit losses	$	3,362,203		$	1,522,784

Bad debt expenses (if any) are recorded in selling, general, and administrative expense.

5. SHARE BASED COMPENSATION

The following table presents share-based compensation expenses for continuing operations included in the Company’s unaudited condensed consolidated statements of operations:

	Three Months Ended March 31,
	2023		2022
Selling, general and administrative	$	55,453	$	92,426
Research, development and engineering		15,922		17,271
	$	71,375	$	109,697

6. INVENTORY

Inventory is stated at the lower of cost, determined on a first in, first out basis, or realizable value. The Company periodically evaluates inventory items and establishes reserves for obsolescence accordingly. The Company also reserves for excess quantities, slow moving goods, and for other impairment of value based upon assumptions of future demand and market conditions. The $400,000 reserve on inventory is due to slow moving inventory purchased for projects in Nigeria. The Company is looking into other markets and opportunities to sell or return the product. Inventory is comprised of the following as of:

	March 31,			December 31,
	2023			2022
Finished goods	$	4,758,089		$	4,764,643
Fabricated assemblies		69,726			69,726
Reserve on finished goods		(400,000	)		(400,000	)
Total inventory	$	4,427,815		$	4,434,369

11

7. COMMITMENTS AND CONTINGENCIES

Distribution Agreement

Swivel Secure has a distribution agreement with Swivel Secure Limited (“SSL”). Terms of the agreement include the following:

1. The initial term of the agreement ends on January 31, 2027 and will be automatically extended for additional one-year terms thereafter unless either party provides written notice to the other party not later than 30 days before the end of the term that it does not wish to extend the term.

2. SSL appoints Swivel Secure as the exclusive distributor of SSL’s products, to market, sell and distribute in the EMEA (Europe, Middle East and Africa), excluding the United Kingdom and Republic of Ireland, for a defined discount on the sale price.

3. Swivel Secure is expected to generate a certain minimum level of orders of SSL products each year during the term of the agreement. If Swivel Secure fails to meet such minimum level of orders in any year, the exclusive distribution rights will terminate and Swivel Secure will serve as a non-exclusive distributer of SSL Products.

The Company expects the revenue targets to continue to be met based on historical performance and increasing distribution by Swivel Secure.

Litigation

From time to time, the Company may be involved in litigation relating to claims arising out of our operations in the normal course of business. As of March 31, 2023, the Company was not a party to any pending lawsuits.

8. LEASES

The Company’s leases office space in New Jersey, Minnesota, New Hampshire, Madrid and Hong-Kong with lease termination dates in 2023 and 2024. The property leased in China is paid monthly as used, without a formal agreement. The following tables present the components of lease expense and supplemental balance sheet information related to the operating leases were:

	3 Months ended March 31, 2023		3 Months ended March 31, 2022
Lease cost
Total lease cost	$	63,139	$	55,219

Balance sheet information	March 31, 2023			December 31, 2022
Operating right-of-use assets	$	131,223		$	197,355
Operating lease liabilities, current portion	$	96,584		$	159,665
Operating lease liabilities, non-current portion		33,366			37,829
Total operating lease liabilities	$	129,950		$	197,494
Weighted average remaining lease term (in years) – operating leases		0.66			0.96
Weighted average discount rate – operating leases		5.50	%		5.50	%
Supplemental cash flow information related to leases were as follows:
Cash paid for amounts included in the measurement of operating lease liabilities for the three months ended March 31, 2023 and 2022:	$	69,821		$	65,108
Maturities of operating lease liabilities were as follows as of March 31, 2023:
2023 (9 months remaining)	$	95,911
2024		38,808
Total future lease payments	$	134,719
Less: imputed interest		(4,769	)
Total	$	129,950

12

9. CONVERTIBLE NOTE PAYABLE

Securities Purchase Agreement dated December 22, 2022

On December 22, 2022, the Company entered into and closed a securities purchase agreement (the “Purchase Agreement”) which issued a $2,200,000 principal amount senior secured promissory note (the “Note”). At closing, a total of $2,002,000 was funded, with the proceeds to be used for general working capital.

The principal amount of the Note is due six months following the date of issuance, subject to one six-month extension by the Company. Interest under the Note accrues at a rate of 10% per annum, payable monthly through month six. In the event the maturity date of the Note is extended, interest will accrue at the rate of 12% per annum in months seven through twelve, payable monthly. The Note is secured by a lien on substantially all of the Company’s assets and properties can be prepaid in whole or in part without penalty at any time.

In connection with the issuance of the Note, the Company issued to the investor 700,000 shares of Common Stock (the “Commitment Shares”) valued at $1.00 per share and a warrant (the “Warrant”) to purchase 200,000 shares of common stock (the “Warrant Shares”) at an exercise price of $3.00 per share, exercisable commencing on the date of issuance with a term of five years. In the event the Note is paid in full within six months after the date of issuance, the Company will exercise its right to repurchase 350,000 of the Commitment Shares for aggregate payment to the Investor of $1.00.

Upon issuance, the Note is not convertible into common stock or any other securities of the Company. Only after a date that is six (6) months following the issuance date of the Note and upon the occurrence of any events of default (as defined) and expiration of any applicable cure periods, all amounts due under the Note will immediately and automatically become due and payable in full, interest will accrue at the higher of 18% per annum or the maximum amount permitted by applicable law, the outstanding principal amount due under the Note will be increased by 30%, and the Investor will have the right to convert all amounts due under the Note into shares of common stock (the “Conversion Shares”) at a conversion price equal to the 10 day volume weighted average sales price of the Company’s common stock on the date of conversion, subject to the Share Cap described in the paragraph below.

The aggregate number of shares of common stock issuable in the forgoing transaction consisting of the Commitment Shares, the Warrant Shares, and the Conversion Shares are capped at 1,684,576 which is 19.9% of the Company’s issued and outstanding shares of common stock on December 22, 2022, the date the definitive transaction documents were executed (the “Share Cap”).

The Company elected the fair value measurement option for the Note as the Note had embedded derivatives that required bifurcation, and recorded the entire hybrid financing instrument at fair value under the guidance of ASC 825, Financial Instruments. As a result, the Note was recorded at fair value upon issuance and is subsequently remeasured at each reporting date until settled or converted. The Company reports interest expense, including accrued interest, related to the Note under the fair value option, separately from within the change in fair value of the Note in the accompanying consolidated statement of operations. See Note 13.

As of March 31, 2023 and December 31, 2022, the Note with principal balance of $2,200,000, at fair value, was recorded at $2,454,212 and $2,596,203, respectively.

13

10. EARNINGS PER SHARE (“EPS”)

The Company’s basic EPS is calculated using net income (loss) available to common shareholders and the weighted-average number of shares outstanding during the reporting period. Diluted EPS includes the effect from potential issuance of common stock, such as stock issuable pursuant to the exercise of stock options and warrants and the assumed conversion of preferred stock.

The following table sets forth options and warrants which were excluded from the diluted per share calculation because the exercise price was greater than the average market price of the common shares:

	Three Months Ended March 31,
	2023		2022
Stock options		202,996		212,461
Warrants		4,872,025		4,689,387
Total		5,075,021		4,901,848

11. STOCKHOLDERS’ EQUITY

Issuances of Common Stock

During the three-month periods ended March 31, 2023, there have not been any shares of common stock issued to anyone outside the Company, except as noted below under Issuances to Directors, Executive Officers & Consultants

On March 8, 2022, the Company issued 269,060 shares of common stock of which 89,687 shares were held back by the Company to secure certain indemnification obligations under the Swivel Secure stock purchase agreement. The shares of Company common stock were issued at a total cost of $600,004, priced at $2.23, based on the contractual 20 day volume-weighted average price of the Company’s common stock immediately prior to the payment date as reported on the Nasdaq Capital Market

Issuances of Restricted Stock

Restricted stock consists of shares of common stock that are subject to restrictions on transfer and risk of forfeiture until the fulfillment of specified conditions. The fair value of nonvested shares is determined based on the market price of the Company's common stock on the grant date. Restricted stock is expensed ratably over the term of the restriction period.

During the three-month periods ended March 31, 2023 and 2022, the Company issued 40,000 and 274,250 shares of restricted common stock to certain employees and the board, respectively. These shares vest in equal annual installments over a three-year period from the date of grant and had a fair value on the date of issuance of $31,200 and $589,638, respectively.

Restricted stock compensation for the three-month period ended March 31, 2023 and 2022 was $59,056 and $39,840, respectively.

14

Issuances to Directors, Executive Officers & Consultants

During the three-month periods ended March 31, 2023 and 2022 the Company issued 15,388 and 9,382 shares of common stock to its directors in lieu of payment of board and committee fees valued at $12,002 and $20,020, respectively.

Employees’ exercise options

During the three-month periods ended March 31, 2023 and 2022, no employee stock options were exercised.

3. Warrants

There were no warrants issued during the three-month periods ended March 31, 2023 and 2022.

12. FAIR VALUES OF FINANCIAL INSTRUMENTS

Cash and cash equivalents, accounts receivable, due from factor, accounts payable and accrued liabilities are carried at, or approximate, fair value because of their short-term nature. The carrying value of the Company’s notes and loan payables approximated fair value as the interest rates related to the financial instruments approximated market.

13. FAIR VALUE MEASUREMENT OF CONVERTIBLE NOTE PAYABLE

Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical unrestricted assets or liabilities;

Level 2: Quoted prices in markets that are not active or inputs which are observable either directly or indirectly for substantially the full term of the asset or liability; and

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity).

The following tables summarize the Note measured at fair value at March 31, 2023 and December 31, 2022:

March 31, 2023	Total		Level 1		Level 2		Level 3
Convertible note at fair value	$	2,454,212	$	-	$	-	$	2,454,212

December 31, 2022	Total		Level 1		Level 2		Level 3
Convertible note at fair value	$	2,596,203	$	-	$	-	$	2,596,203

The Company estimated the fair value of the convertible note using a probability-weighted discounted cash flow model with the following assumptions and significant terms of the convertible note at both March 31, 2023 and December 31, 2022:

1. Face amount - $2,200,000

2. Nominal interest rate – 10% - 12%

3. Default interest rate – 18%

4. Increase in principal upon a default – 30%

5. Present value discount rate – 15.04% at March 31, 2023 and 15.18% at December 31, 2022

6. Likelihood of default – estimated to be 50% at the extended maturity date

The following table shows the changes in fair value measurements for the convertible note using significant unobservable inputs (Level 3) during the three months ended March 31, 2023:

Beginning balance	$	2,596,203
Purchases and issuances		-
Change in fair value		(141,991	)
Ending balance	$	2,454,212

15

14. MAJOR CUSTOMERS AND ACCOUNTS RECEIVABLE

For the three month periods ended March 31, 2023 and 2022, two customers accounted for 48% and one customer accounted for 27% of revenues, respectively. Two customers accounted for 45% of current accounts receivable as of March 31, 2023. At December 31, 2022, one customers accounted for 35% of current accounts receivable.

15. INCOME TAXES

The Company recorded no income tax expense for the three months ended March 31, 2023 and 2022 because the estimated annual effective tax rate was zero. In determining the estimated annual effective income tax rate, the Company analyses various factors, including projections of the Company’s annual earnings and taxing jurisdictions in which the earnings will be generated, the impact of state and local income taxes, the ability to use tax credits and net operating loss carry forwards, and available tax planning alternatives.

As of March 31, 2023 and December 31, 2022, the Company provided a full valuation allowance against its net deferred tax assets since the Company believes it is more likely than not that its deferred tax assets will not be realized.

16. SUBSEQUENT EVENTS

On May 5, 2023, the Company issued 2,858 shares of common stock to its directors in payment of board committee fees.

On May 5, 2023, 14,375 shares of restricted common stock were cancelled as a result of employees leaving the Company before the vesting period was completed.

On May 11, 2023, the Company issued 17,392 shares of common stock to its directors in payment of board fees.

On May 11, 2023, the Company issued 2,900 shares of common stock to its directors in payment of board committee fees.

16

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including statements regarding our future financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. The words “anticipate,” “believe,” “should,” “estimate,” “will,” “may,” “future,” “plan,” “intend” and “expect” and similar expressions generally identify forward-looking statements. These statements are not guarantees of future performance or events and are subject to risks and uncertainties that may cause actual results to differ materially from those included within or implied by such forward-looking statements. These risks and uncertainties include, without limitation, our history of losses and limited revenue; our ability to raise additional capital; our ability to protect our intellectual property; changes in business conditions; changes in our sales strategy and product development plans; changes in the marketplace; continued services of our executive management team; security breaches; competition in the biometric technology and identity access management industries; market acceptance of biometric products generally and our products under development; our ability to execute and deliver on contracts in Africa; our ability to expand into Asia, Africa and other foreign markets; our ability to integrate the operations and personnel of Swivel Secure into our business; fluctuations in foreign currency and exchange rates; the duration and extent of continued hostilities in Ukraine and its impact on our European customers; delays in the development of products, statements of assumption underlying any of the foregoing, and numerous other matters of national, regional and global scale, including those set forth under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2022 and other filings with the Securities and Exchange Commission (“SEC”). These factors are not intended to represent a complete list of the general or specific factors that may affect us. It should be recognized that other factors, including general economic factors and business strategies, may be significant, presently or in the future. Except as required by law, we undertake no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

ITEM 2.    MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIONS AND RESULTS OF OPERATIONS.

This Management’s Discussion and Analysis of Financial Condition and Results of Operations is provided as a supplement to and should be read in conjunction with our unaudited condensed consolidated financial statements and related information contained herein and our audited financial statements as of December 31, 2022.

Overview

BIO-key International, Inc. (the “Company,” “BIO-key,” “we,” or “us”) is a leading identity and access management (IAM) platform provider enabling secure work-from-anywhere for enterprise, education, and government customers using secure multi-factor authentication (MFA).  Our vision is to enable any organization to secure streamlined and passwordless workforce, customer, citizen and student access to any online service, workstation, or mobile application, without a requirement to use tokens or phones.  Our products include PortalGuard® and PortalGuard Identity-as-a-Service (IDaaS) enterprise IAM, WEB-key® biometric civil and large-scale ID infrastructure, MobileAuth® mobile phone authentication application for iOS and Android, and high-quality, low-cost accessory fingerprint scanner and FIDO-compliant hardware to provide a full and complete solution for identity-innovating customers.

BIO-key PortalGuard and hosted PortalGuard IDaaS are platforms that enable our customers to securely and easily assure that only the right people can access the right systems.  PortalGuard goes beyond traditional MFA solutions by addressing functional gaps, such as allowing roving users to biometrically authenticate at any workstation without using their phones or tokens, eliminating unauthorized account delegation, detecting duplicate users, and accommodating in-person identification.

Our customers use BIO-key every day to securely access a variety of cloud, mobile and web applications, on-premise and cloud-based servers from all of their devices. Employees, contractors, students and faculty sign in through PortalGuard to seamlessly and securely access the applications they need to do their important work, without relying on personal phone use or per-user tokens. Organizations use our platform to securely collaborate with their supply chain and partners, and to provide their customers with flexible, resilient user experiences online or in-person.

Large-scale customer and civil ID customers use our scalable biometric management platform and FBI-certified scanner hardware to manage enrollment, de-duplication and authentication for millions of users. One large bank has enrolled and identifies over 21.7 million of their customers using BIO-key fingerprint biometrics in branches on a daily basis.

PortalGuard and hosted PortalGuard IDaaS are platforms that enable our customers to securely and easily assure that only the right people can access the right systems by utilizing our world-class biometric core platform among 17 other authentication factors.  PortalGuard goes beyond traditional multi-factor authentication, or MFA, solutions by addressing sizeable gaps, such as allowing roving users to biometrically authenticate at any workstation without using their phones or tokens, eliminating unauthorized account delegation, detecting duplicate users, and accommodating in-person identification.

PortalGuard and IBB deliver unique value to enterprises who find that mainstream MFA solutions do not adequately address their workforce use cases.  PortalGuard operates as a single MFA user experience, providing a rich set of authentication choices to meet every use case.  We sell our branded biometric and FIDO authentication hardware as accessories to our IAM platforms, so that customers can have a single vendor providing all components of their IAM solution. We do not mandate the use of BIO-key hardware with our software and services. Our NIST-certified fingerprint biometric platform is unique in that it supports interoperable mixing and matching combinations of different manufactures’ fingerprint scanners in a deployment, so that the right scanner can be selected for the right use case, without mandating the user of a particular scanner.

Security-conscious software developers leverage our platform APIs and federation interfaces to securely and efficiently embed biometric and MFA identity capabilities into their software.   Our approach to IDaaS allows our customers to efficiently scale their security and identity infrastructures to protect both internal cloud workforce- and external customer-facing applications.

In 2022, we expanded our product offerings and customer base when we acquired Swivel Secure, a Madrid, Spain based provider of IAM solutions.  Swivel Secure is the exclusive distributer of AuthControl Sentry, AuthControl Enterprise, and AuthControl MSP product line in Europe, Africa and the Middle East, or EMEA, excluding the United Kingdom and Ireland.  These solutions include a patented one-time-code extraction technology, helping enterprises manage the increasing data security risks posed by cloud services and bring your own device policies.

We operate a SaaS business model with customers subscribing to term use of our software for annual recurring revenue. We sell our products directly through our field and inside sales teams, as well as indirectly through our network of channel partners including resellers, system integrators, master agents and other distribution partners. Our subscription fees include a term license of hosted or on-premise product and technical support and maintenance of our platform. We base subscription fees primarily on the products used and the number of users enrolled in our platform. We generate subscription fees pursuant to noncancelable contracts with a weighted average duration of approximately one year.

17

Strategic Outlook

We plan to have a more significant role in the IAM market which continues to expand. We plan to offer customers a suite of authentication options that complement our biometric solutions. The more well-rounded offerings of authentication options will allow customers to customize their approach to authentication all under one umbrella.

We expect to grow our business within government services and highly-regulated industries in which we have historically had a strong presence including financial services, higher education, and healthcare.  We believe that continued heightened security and privacy requirements in these industries, and as colleges and universities continue operating in remote environments, we will generate increased demand for security solutions, including biometrics. In addition, we expect that the compatible, yet superior portable biometric user experience offered by our technology for Windows 10 users will accelerate the demand for our computer network log-on solutions and fingerprint readers.  Through value add-offerings via direct sales, resellers, and strategic partnerships with leading higher education platform providers, we will continue to grow our installed base.

Our primary sales strategies are focused on (i) increased marketing efforts into the IAM market, (ii) dedicated pursuit of large-scale identification projects across the globe and (iii) growing our channel alliance program which we have grown to more than one hundred and fifty participants and continues to generate incremental revenues.

A second component of our growth strategy is to pursue strategic acquisitions of select businesses and assets in the IAM space.  In furtherance of this strategy, we are active in the industry and regularly evaluate businesses that we believe will either provide an entry into new market verticals or be synergistic with our existing operations and in either case, be accretive to earnings.  We cannot provide any assurance as to whether we will be able to complete any acquisition and if completed, successfully integrate any business we acquire into our operations.

Critical Accounting Policies and Estimates

For detailed information regarding our critical accounting policies and estimates, see our financial statements and notes thereto included in this Report and in our Annual Report on Form 10-K for the year ended December 31, 2022.  There have been no material changes to our critical accounting policies and estimates from those disclosed in our most recent Annual Report on Form 10-K.

Recent Accounting Pronouncements

For detailed information regarding recent account pronouncements, see Notes to Condensed Consolidated Financial Statements included in Part I, Item 1 of this report.

18

RESULTS OF OPERATIONS

THREE MONTHS ENDED MARCH 31, 2023 AS COMPARED TO MARCH 31, 2022

Consolidated Results of Operations - Percent Trend

	Three Months Ended March 31,
	2023			2022
Revenues
Services		17	%		20	%
License fees		81	%		75	%
Hardware		2	%		5	%
Total Revenues		100	%		100	%
Costs and other expenses
Cost of services		5	%		10	%
Cost of license fees		20	%		4	%
Cost of hardware		1	%		3	%
Total Cost of Goods Sold		26	%		17	%
Gross profit		74	%		83	%
Operating expenses
Selling, general and administrative		63	%		93	%
Research, development and engineering		22	%		41	%
Total Operating Expenses		85	%		134	%
Operating loss		-11	%		-51	%
Other income (expenses)		2	%		-	%
Net loss		-9	%		-51	%

Revenues and cost of goods sold

	Three months ended
	March 31,
	2023		2022		$ Change			% Change
Revenues
Service	$	532,522	$	395,804	$	136,718			35	%
License		2,478,556		1,460,183		1,018,373			70	%
Hardware		72,689		85,184		(12,495	)		-15	%
Total Revenue	$	3,083,767	$	1,941,171	$	1,142,596			59	%
Cost of goods sold
Service	$	154,801	$	210,913	$	(56,112	)		-27	%
License		620,881		73,230		547,651			748	%
Hardware		44,592		53,298		(8,706	)		-16	%
Total Cost of goods sold	$	820,274	$	337,441	$	482,833			143	%

Revenues

For the three months ended March 31, 2023 and 2022, service revenues included approximately $292,000 and $317,000 respectively, of recurring maintenance and support revenue, and approximately $240,000 and $79,000, respectively, of non-recurring custom services revenue.  Recurring service revenue decreased 13% in the first quarter of 2023 as compared to the first quarter of 2022 due largely to the recognition of annual SaaS revenue versus maintenance renewal contracts. Non-recurring custom services increased due to services provided by Swivel Secure. As our customer base continues to grow, we expect the service revenue to increase in future periods.

19

For the three months ended March 31, 2023, license revenue increased 70% to $2,478,556 from $1,460,183 during the three months ended March 31, 2022. We increased both the industry variation and number of customers, including additional revenue from Swivel Secure which generated 63% of its license revenue from a customer in Central America, one large SaaS renewal, and cloud migrations.

Hardware sales decreased $12,495 during the three months ended March 31, 2023 to $72,689 from $85,184 during the three months ended March 31, 2022. The decrease was attributable to the mix of installations and other projects completed in the periods.

Costs of goods sold

For the three months ended March 31, 2023, cost of service decreased approximately $56,000 or 27% to $154,801 from $210,913 for the three months ended March 31, 2022 due to reduced personnel costs associated with the direct support for BIO-key support and maintenance,. For the three months ended March 31, 2022, license fees increased to $620,881 from $73,230 during the three months ended March 31, 2022, due largely to the costs related to the license for the Swivel Secure product line. For the three months ended March 31, 2023, hardware costs decreased to $44,592 from $53,298 during the three months ended March 31, 2022, corresponding to the decrease in hardware revenue.

Selling, general and administrative

	Three months ended
	March 31,
	2023		2022		$ Change		% Change
Selling, general and administrative	$	1,931,732	$	1,797,998	$	133,734		7	%

Selling, general and administrative expenses for the three months ended March 31, 2023 increased 5% to $1,931,732 as compared to $1,797,998 for the corresponding period in 2022. This increase was attributable largely to a full quarter of Swivel Secure sales expenses and a reserve for doubtful accounts of $50,000. These increases were offset, in part, by decreases in marketing personnel and expenses, and non-cash compensation.

Research, development and engineering

	Three months ended
	March 31,
	2023		2022		$ Change			% Change
Research, development and engineering	$	690,159	$	805,266	$	(115,107	)		-14	%

For the three months ended March 31, 2023, research, development and engineering expenses decreased 14% to $690,159 as compared to $805,266 for the corresponding period in 2022. Included in the decrease were reductions in personnel costs, and outside services related to the completed development of our MobileAuth application.

Other income (expense)

	Three months ended
	March 31,
	2023			2022		$ Change			% Change
Other income (expenses)
Interest income	$	4		$	131	$	(127	)		-97	%
Loss on foreign currency transactions		(15,000	)		-		(15,000	)		-100	%
Change in fair value of convertible note		141,991			-		141,991			100	%
Interest expense		(56,919	)		-		(56,919	)		-100	%
Other income (expense)	$	70,076		$	131	$	69,945			553,931	%

Other income (expense) for the three month period ended March 31, 2023 consisted of interest expense of $54,999 on the secured note payable plus the government loan through the BBVA bank net of interest income, change in fair value of $141,991 on the convertible note payable, and loss on foreign currency transactions. Other income (expense) for the three month period ended March 31, 2022 consisted of interest income.

20

LIQUIDITY AND CAPITAL RESOURCES

Cash Flows

Operating activities overview

Net cash used for operations during the three months ended March 31, 2023 was $1,928,811. Items of note included:

● Net positive cash flows related to accounts payable, prepayments, inventory and deferred revenue of approximately $276,000. 

● Net positive cash flows related to adjustments for non-cash expenses of approximately $128,000

● Negative cash flows related to changes in accounts receivable, amount due from factor, and accrued liabilities of approximately $2.3 million, due to working capital management.

Financing activities overview

Net cash used for financing during the three months ended March 31, 2023 was $34,289 for repayment of the government loan through the BBVA bank.

We did not use or generate any cash for investing activities during the three months ended March 31, 2023.

Liquidity and Capital Resources

Since our inception, our capital needs have been principally met through proceeds from the sale of equity and debt securities. We expect capital expenditures to be less than $100,000 during the next twelve months.

The following sets forth our primary sources of capital during the previous two years:

In December 2022, we entered into and closed a securities purchase agreement (the “Purchase Agreement”) with AJB Capital Investments, LLC under which we issued a $2,200,000 principal amount senior secured promissory note (the “Note”). The principal amount of the Note is due six months following the date of issuance, subject to one six-month extension. Interest under the Note accrues at a rate of 10% per annum, payable monthly through month six. In the event the maturity date of the Note is extended, interest will accrue at the rate of 12% per annum in months seven through twelve, payable monthly. The Note is secured by a lien on substantially all of the Company’s assets and properties can be prepaid in whole or in part without penalty at any time.

In March 2022, in connection with the acquisition of Swivel Secure, we assumed a €500,000 government loan that was issued through BBVA Bank during the COVID-19 pandemic.  The loan bears interest at the rate of 1.75% per annum and is payable in monthly installments of approximately $11,900 inclusive of interest from May 2022 through maturity in April 2026. Upon closing of the acquisition, Swivel Secure had cash equal to the outstanding balance.

We entered into an accounts receivable factoring arrangement with a financial institution (the “Factor”) which has been extended to October 31, 2023 and may be discontinued at that time. Pursuant to the terms of the arrangement, from time to time, we sell to the Factor a minimum of $150,000 per quarter of certain of our accounts receivable balances on a non-recourse basis for credit approved accounts. The Factor remits 35% of the foreign and 75% of the domestic accounts receivable balance to us (the “Advance Amount”), with the remaining balance, less fees, forwarded to us once the Factor collects the full accounts receivable balance from the customer. In addition, from time to time, we receive over advances from the Factor. Factoring fees range from 2.75% to 15% of the face value of the invoice factored and are determined by the number of days required for collection of the invoice. We expect to continue to use this factoring arrangement periodically to assist with our general working capital requirements due to contractual requirements

Liquidity outlook

At March 31, 2023, our total cash and cash equivalents were $722,335, as compared to approximately $2,635,522 at December 31, 2022.  At March 31, 2023, we had working capital of approximately $3,511,000.

As discussed above, we have historically financed our operations through access to the capital markets by issuing secured and convertible debt securities, convertible preferred stock, common stock, and through factoring receivables. We currently require approximately $798,000 per month to conduct our operations, a monthly amount that we have been unable to consistently achieve through revenue generation.  During for the first three months of 2023, we generated $3,083,767 of revenue which did not generate enough cash to fully fund our average monthly requirements. We expect that Swivel Secure will start to generate positive cash flow in 2023. We also have approximately $3.8 million of inventory purchased for projects in Nigeria. We are looking into other markets and opportunities to sell or return the product to generate additional cash.

If we are unable to generate sufficient revenue to fund current operations and execute our business plan, we may need to obtain additional third-party financing. Our secured note is due on June 22, 2023 which we expect to extend for an additional six months.  Unless we generate sufficient positive cash flow from operations or liquidation of existing inventory, we expect that we will need to obtain additional financing during the next twelve months to be used in part to repay our outstanding secured note.

Our long-term viability and growth will depend upon the successful commercialization of our technologies and our ability to obtain adequate financing. To the extent that we require such additional financing, no assurance can be given that any form of additional financing will be available on terms acceptable to us, that adequate financing will be obtained to meet our needs, or that such financing would not be dilutive to existing stockholders. If available financing is insufficient or unavailable or we fail to continue to generate sufficient revenue, we may be required to further reduce operating expenses, delay the expansion of operations, be unable to pursue merger or acquisition candidates, or in the extreme case, not continue as a going concern.

21

ITEM 4. CONTROLS AND PROCEDURES. 

Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2023. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate, to allow timely decisions regarding required disclosure. Based on the evaluation of our disclosure controls and procedures as of March 31, 2023, our CEO and CFO concluded that, as of such date, our disclosure controls and procedures were not effective to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act was recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. 

Changes in Internal Control Over Financial Reporting

As reported in our 10-K for the year ended December 31, 2022, in connection with the audit of our financial statements as of and for the year ended December 31, 2022, our management identified a material weakness relating to the effectiveness of management’s review and controls over the income tax provision in our financial footnotes, such that management’s review procedures were not operating at a level of precision to prevent or detect a potential material misstatement in our consolidated financial statements. We have also identified a lack of control over our foreign subsidiaries with respect to the filing of required tax returns on a timely basis.

We are currently in the process of engaging a consultant to review transactions for appropriate technical accounting, reconcile accounts, review significant transactions and assist with the preparation of financial statements.  Other than the forgoing, there have been no changes in our internal control over financial reporting during the fiscal quarter ended March 31, 2023, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II — OTHER INFORMATION

ITEM 6. Exhibits 

The following exhibits are being filed or furnished with this quarterly report on Form 10-Q.

Exhibit No.	Description
31.1*	Certificate of CEO of Registrant required under Rule 13a-15(f) under the Securities Exchange Act of 1934, as amended
31.2*	Certificate of CFO of Registrant required under Rule 13a-15(f) under the Securities Exchange Act of 1934, as amended
32.1*	Certificate of CEO of Registrant required under 18 U.S.C. Section 1350
32.2*	Certificate of CFO of Registrant required under 18 U.S.C. Section 1350
101.INS	Inline XBRL Instance
101.SCH	Inline XBRL Taxonomy Extension Schema
101.CAL	Inline XBRL Taxonomy Extension Calculation
101.DEF	Inline XBRL Taxonomy Extension Definition
101.LAB	Inline XBRL Taxonomy Extension Labels
101.PRE	Inline XBRL Taxonomy Extension Presentation
104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

*  Filed herewith.

+  Certain portions of this exhibit (indicated by “[***]”) have been omitted as the Registrant has determined that such portions are (a) not material and (b) would likely cause competitive harm to the Registrant if publicly disclosed.

22

SIGNATURES 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	BIO-Key International, Inc.
Dated: June 9, 2023	/s/ MICHAEL W. DEPASQUALE
	Michael W. DePasquale
	Chief Executive Officer
Dated: June 9, 2023	/s/ CECILIA C. WELCH
	Cecilia C. Welch
	Chief Financial Officer

23

EX-31.1

Exhibit 31.1

CERTIFICATION

I, Michael W. DePasquale, certify that: 

1. I have reviewed this quarterly report on Form 10-Q of BIO-key International, Inc. (the “Company”);

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report;

4. The Company’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the Company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and 

(d) Disclosed in this report any change in the Company’s internal control over financial reporting that occurred during the Company’s most recent fiscal quarter (the Company’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the company’s internal control over financial reporting; 

5. The Company’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company’s auditors and the audit committee of the Company’s board of directors (or persons performing the equivalent functions): 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company’s ability to record, process, summarize and report financial information; and 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s internal control over financial reporting.

Dated: June 9, 2023
	/s/ Michael W. DePasquale
	Michael W. DePasquale
	Chief Executive Officer

EX-31.2

Exhibit 31.2

CERTIFICATION

I, Cecilia C. Welch, certify that: 

1. I have reviewed this quarterly report on Form 10-Q of BIO-key International, Inc. (the “Company”);

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report;

4. The Company’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the Company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the Company’s internal control over financial reporting that occurred during the Company’s most recent fiscal quarter (the Company’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the company’s internal control over financial reporting; 

5. The Company’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company’s auditors and the audit committee of the Company’s board of directors (or persons performing the equivalent functions): 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company’s ability to record, process, summarize and report financial information; and 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s internal control over financial reporting.

Dated: June 9, 2023
	/s/ Cecilia C. Welch
	Cecilia C. Welch
	Chief Financial Officer

EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of BIO-key International, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Michael W. DePasquale, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

(1)  The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)  The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

BIO-KEY INTERNATIONAL, INC.
By:	/s/ Michael W. DePasquale
	Michael W. DePasquale
	Chief Executive Officer
Dated: June 9, 2023

EX-32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of BIO-key International, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Cecilia Welch, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of The Sarbanes-Oxley Act of 2002, that to my knowledge:

(1)  The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)  The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

BIO-KEY INTERNATIONAL, INC.
By:	/s/ Cecilia C. Welch
	Cecilia C. Welch
	Chief Financial Officer
Dated: June 9, 2023

XML

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2023	Jun. 08, 2023
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2023
Document Transition Report	false
Entity File Number	1-13463
Entity Registrant Name	BIO-KEY INTERNATIONAL, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	41-1741861
Entity Address, Address Line One	3349 HIGHWAY 138, BUILDING A, SUITE E
Entity Address, City or Town	WALL
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	07719
City Area Code	732
Local Phone Number	359-1100
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	BKYI
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding (in shares)		9,234,833
Entity Central Index Key	0001019034
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q1
Amendment Flag	false

XML

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
ASSETS
Cash and cash equivalents	$ 722,335	$ 2,635,522
Accounts receivable, net	3,362,203	1,522,784
Due from factor	82,500	49,500
Inventory, net of reserve	4,427,815	4,434,369
Prepaid expenses and other	341,231	342,706
Total current assets	8,936,084	8,984,881
Equipment and leasehold improvements, net	94,170	107,413
Capitalized contract costs, net	254,279	283,069
Deposits and other assets	8,712	8,712
Operating lease right-of-use assets	131,223	197,355
Intangible assets, net	1,681,589	1,762,825
Total non-current assets	2,169,973	2,359,374
TOTAL ASSETS	11,106,057	11,344,255
LIABILITIES
Accounts payable	1,210,070	1,108,279
Accrued liabilities	876,287	1,009,123
Convertible note payable, net of debt discount	2,454,212	2,596,203
Government loan – BBVA Bank, current portion	134,899	120,000
Deferred revenue - current	653,338	462,418
Operating lease liabilities, current portion	96,584	159,665
Total current liabilities	5,425,390	5,455,688
Deferred revenue, net of current portion	39,969	52,134
Deferred tax liability	172,997	170,281
Government loan – BBVA Bank, net of current portion	277,580	326,767
Operating lease liabilities, net of current portion	33,366	37,829
Total non-current liabilities	523,912	587,011
TOTAL LIABILITIES	5,949,302	6,042,699
Commitments and Contingencies
STOCKHOLDERS’ EQUITY
Common stock — authorized, 170,000,000 shares; issued and outstanding; 9,190,504 and 7,853,759 of $.0001 par value at December 31, 2022 and December 31, 2021, respectively	922	919
Additional paid-in capital	122,099,984	122,028,612
Accumulated other comprehensive loss	(170,456)	(242,602)
Accumulated deficit	(116,773,695)	(116,485,373)
TOTAL STOCKHOLDERS’ EQUITY	5,156,755	5,301,556
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 11,106,057	$ 11,344,255

XML

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Mar. 31, 2023	Dec. 31, 2022
Common stock, shares authorized (in shares)	170,000,000	170,000,000
Common Stock, Shares, Issued (in shares)	9,226,058	9,190,504
Common stock, shares outstanding (in shares)	9,226,058	9,190,504
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001

XML

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenues
Total revenues	$ 3,083,767	$ 1,941,171
Costs and other expenses
Total costs and other expenses	820,274	337,441
Gross Profit	2,263,493	1,603,730
Operating expenses
Selling, general and administrative	1,931,732	1,797,998
Research, development and engineering	690,159	805,266
Total operating expenses	2,621,891	2,603,264
Operating loss	(358,398)	(999,534)
Other income (expense)
Interest income	4	131
Loss on foreign currency transactions	(15,000)	0
Change in fair value of convertible note	141,991	0
Interest expense	(56,919)	0
Total other income (expense)	70,076	131
Net loss	(288,322)	(999,403)
Comprehensive loss:
Net loss	(288,322)	(999,403)
Other comprehensive loss- Foreign translation adjustment	72,146	55,802
Comprehensive loss	$ (216,176)	$ (943,601)
Basic and Diluted Loss per Common Share (in dollars per share)	$ (0.03)	$ (0.13)
Weighted Average Shares Outstanding:
Basic and Diluted (in shares)	8,944,485	7,885,008
Service [Member]
Revenues
Total revenues	$ 532,522	$ 395,804
Costs and other expenses
Total costs and other expenses	154,801	210,913
License [Member]
Revenues
Total revenues	2,478,556	1,460,183
Costs and other expenses
Total costs and other expenses	620,881	73,230
Hardware [Member]
Revenues
Total revenues	72,689	85,184
Costs and other expenses
Total costs and other expenses	$ 44,592	$ 53,298

XML

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2021	7,853,759
Balance at Dec. 31, 2021	$ 786	$ 120,190,139	$ 0	$ (104,575,470)	$ 15,615,455
Issuance of common stock for directors’ fees (in shares)	9,382
Issuance of common stock for directors’ fees	$ 1	22,019	0	0	22,020
Issuance of restricted common stock to employees (in shares)	274,250
Issuance of restricted common stock to employees	$ 27	(27)	0	0	0
Other comprehensive loss- Foreign translation adjustment			55,802	0	55,802
Share-based compensation	0	87,677	0	0	87,677
Net loss	$ 0	0	0	(999,403)	(999,403)
Issuance of common stock pursuant to Swivel purchase agreement (in shares)	269,060
Issuance of common stock pursuant to Swivel purchase agreement	$ 27	599,977	0	0	600,004
Net loss	$ 0	0	0	(999,403)	(999,403)
Balance as of December 31, 2021 (in shares) at Mar. 31, 2022	8,406,451
Balance as of December 31, 2021 at Mar. 31, 2022	$ 841	122,099,785	55,802	(105,574,873)	15,381,555
Balance (in shares) at Dec. 31, 2022	9,190,504
Balance at Dec. 31, 2022	$ 919	122,028,612	(242,602)	(116,485,373)	5,301,556
Issuance of common stock for directors’ fees (in shares)	15,388
Issuance of common stock for directors’ fees	$ 1	12,001	0	0	12,002
Issuance of restricted common stock to employees (in shares)	40,000
Issuance of restricted common stock to employees	$ 4	0	0	0	4
Forfeiture of restricted stock (in shares)	(19,834)
Forfeiture of restricted stock	$ (2)	(3,103)	0	0	(3,105)
Other comprehensive loss- Foreign translation adjustment			72,146	0	72,146
Share-based compensation	0	62,474	0	0	62,474
Net loss	0	0	0	(288,322)	(288,322)
Net loss	$ 0	0	0	(288,322)	(288,322)
Balance as of December 31, 2021 (in shares) at Mar. 31, 2023	9,226,058
Balance as of December 31, 2021 at Mar. 31, 2023	$ 922	$ 122,099,984	$ (170,456)	$ (116,773,695)	$ 5,156,755

XML

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
CASH FLOW FROM OPERATING ACTIVITIES:
Net loss	$ (288,322)	$ (999,403)
Adjustments to reconcile net loss to cash used for operating activities:
Depreciation	13,242	11,220
Amortization of intangible assets and write-off	81,237	54,231
Change in fair value of convertible note	(141,991)	(0)
Amortization of capitalized contract costs	37,529	35,658
Amortization of operating lease right-of-use assets	66,132	51,587
Stock based fees to directors	12,002	22,020
Share based and warrant compensation for employees and consultants	59,373	87,677
Bad debt expense	0	25,111
Change in operating assets and liabilities:
Accounts receivable	(1,798,881)	(904,930)
Due from factor	(33,000)	(2,350)
Capitalized contract costs	(8,739)	(66,435)
Inventory	6,554	(15,812)
Resalable software license rights	0	2,505
Prepaid expenses and other	2,219	(124,616)
Accounts payable	88,040	175,341
Accrued liabilities	(135,417)	45,669
Deferred revenue	178,755	220,874
Operating lease liabilities	(67,544)	(52,722)
Net cash used for operating activities	(1,928,811)	(1,434,375)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of Swivel Secure, net of cash acquired of $729,905	0	(543,578)
Receipt of cash from note receivable	0	3,000
Capital expenditures	(0)	4,459
Net cash used for investing activities	0	(545,037)
CASH FLOW FROM FINANCING ACTIVITIES:
Repayment of government loan	(34,289)	0
Net cash used in financing activities	(34,289)	0
Effect of exchange rate changes	49,913	26,487
NET DECREASE IN CASH AND CASH EQUIVALENTS	(1,913,187)	(1,952,925)
CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR	2,635,522	7,754,046
CASH AND CASH EQUIVALENTS, END OF YEAR	722,335	5,801,121
Cash paid for:
Interest	56,919	0
Noncash Investing and financing activities
Accounts receivable acquired from Swivel Secure	0	702,886
Equipment acquired from Swivel Secure	0	65,640
Other assets acquired from Swivel Secure	0	20,708
Estimated intangible assets acquired from Swivel Secure	0	1,379,589
Estimated goodwill resulting from the acquisition from Swivel Secure	0	450,643
Accounts payable and accrued expenses acquired from Swivel Secure	0	431,884
Government loan acquired from Swivel Secure	0	544,000
Common stock issued for acquisition of Swivel Secure	$ 0	$ 600,004

XML

Condensed Consolidated Statements of Cash Flows (Unaudited) (Parentheticals)	3 Months Ended
	Mar. 31, 2022 USD ($)
Receipt of cash from note receivable	$ 3,000
Swivel Secure Europe [Member]
Receipt of cash from note receivable	$ 729,905

XML

Note 1 - Nature of Business and Basis of Presentation

3 Months Ended

Mar. 31, 2023

Notes to Financial Statements

Business Description and Accounting Policies [Text Block]

1. NATURE OF BUSINESS AND BASIS OF PRESENTATION

Nature of Business

The Company, founded in 1993, develops and markets proprietary fingerprint identification biometric technology and software solutions enterprise-ready identity access management solutions to commercial, government and education customers throughout the United States and internationally. The Company was a pioneer in developing automated, finger identification technology that supplements or compliments other methods of identification and verification, such as personal inspection identification, passwords, tokens, smart cards, ID cards, PKI, credit cards, passports, driver’s licenses, OTP or other form of possession or knowledge-based credentialing. Additionally, advanced BIO-key® technology has been, and is, used to improve both the accuracy and speed of competing finger-based biometrics.

Basis of Presentation

The accompanying unaudited interim condensed consolidated financial statements include the accounts of BIO-key International, Inc. and its wholly-owned subsidiaries (collectively, the “Company” or “BIO-key”) and are stated in conformity with accounting principles generally accepted in the United States of America (“GAAP”), pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). The operating results for interim periods are not necessarily indicative of results that may be expected for any other interim period or for the full year. Pursuant to such rules and regulations, certain financial information and footnote disclosures normally included in the financial statements have been condensed or omitted. Intercompany accounts and transactions have been eliminated in consolidation.

In the opinion of management, the accompanying unaudited interim consolidated financial statements contain all necessary adjustments, consisting only of those of a recurring nature, and disclosures to present fairly the Company’s financial position and the results of its operations and cash flows for the periods presented. The balance sheet at December 31, 2022 was derived from the audited financial statements, but does not include all of the disclosures required by GAAP. These unaudited interim condensed consolidated financial statements should be read in conjunction with the financial statements and the related notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the SEC on June 1, 2023.

Foreign Currencies

The Company accounts for foreign currency transactions pursuant to ASC 830, Foreign Currency Matters ("ASC 830”). The functional currency of the Company is the U.S. dollar, which is the currency of the primary economic environment in which it operates. In accordance with ASC 830, all assets and liabilities are translated into U. S. dollars using the current exchange rate at the end of each fiscal period. Revenues and expenses are translated using the average exchange rates prevailing throughout the respective periods. All transaction gains and losses from the measurement of monetary balance sheet items denominated in Euros are reflected in the statement of operations as appropriate. Translation adjustments are included in accumulated other comprehensive income (loss).

Recently Issued Accounting Pronouncements

Effective January 1, 2023, the Company adopted ASU 2016-13, Financial Instruments-Credit Losses (Topic 326), referred to herein as ASU 2016-13, which significantly changes how entities will account for credit losses for most financial assets and certain other instruments that are not measured at fair value through net income. ASU 2016-13 replaces the existing incurred loss model with an expected credit loss model that requires entities to estimate an expected lifetime credit loss on most financial assets and certain other instruments. Under ASU 2016-13 credit impairment is recognized as an allowance for credit losses, rather than as a direct write-down of the amortized cost basis of a financial asset. The impairment allowance is a valuation account deducted from the amortized cost basis of financial assets to present the net amount expected to be collected on the financial asset. Once the new pronouncement is adopted by the Company, the allowance for credit losses must be adjusted for management’s current estimate at each reporting date. The new guidance provides no threshold for recognition of impairment allowance. Therefore, entities must also measure expected credit losses on assets that have a low risk of loss. For instance, trade receivables that are either current or not yet due may not require an allowance reserve under currently generally accepted accounting principles, but under the new standard, the Company will have to estimate an allowance for expected credit losses on trade receivables under ASU 2016-13. The adoption of ASU 2016-13 did not have a material effect on the consolidated financial statements of the Company. 

In August 2020, the Financial Accounting Standards Board issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40) (“ASU 2020-06”) to simplify accounting for certain financial instruments. ASU 2020-06 eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity’s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity’s own equity. ASU 2020-06 amends the diluted earnings per share guidance, including the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective for the Company on January 1, 2024 and should be applied on a full or modified retrospective basis. The Company is currently assessing the impact ASU 2020-06 will have on its consolidated financial statements.

Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying consolidated financial statements.

XML

Note 2 - Going Concern

3 Months Ended

Mar. 31, 2023

Notes to Financial Statements

Substantial Doubt about Going Concern [Text Block]

2. GOING CONCERN

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP"), which contemplate continuation of the Company as a going concern, and assumes continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company has suffered substantial net losses and negative cash flows from operations in recent years and is dependent on debt and equity financing to fund its operations all of which raise substantial doubt about the Company’s ability to continue as a going concern. Recoverability of a major portion of the recorded asset amounts shown in the accompanying balance sheet is dependent upon the Company’s ability to increase its revenue and meet its financing requirements on a continuing basis and become profitable in its future operations. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence.

As of the date of this report, the Company does not have enough cash for twelve months of operations. The history of significant losses, the negative cash flow from operations, the limited cash resources on hand and the dependence by the Company on its ability to obtain additional financing to fund its operations after the current cash resources are exhausted raises substantial doubt about the Company's ability to continue as a going concern. The Company has lowered its expenses through decreasing spending in marketing and research and development. In addition, the Company has purchased inventory for projects in Nigeria, which have been delayed in deployment, and is, therefore, looking into other markets and opportunities to sell or return the product to generate additional cash.

XML

Note 3 - Revenue From Contracts With Customers

3 Months Ended

Mar. 31, 2023

Notes to Financial Statements

Revenue from Contract with Customer [Text Block]

3. REVENUE FROM CONTRACTS WITH CUSTOMERS

Disaggregation of Revenue

The following table summarizes revenue from contracts with customers for the three-month period:

	North America		Africa		EMESA*		Asia		March 31, 2023
License fees	$	408,530	$	552,630	$	1,446,746	$	70,650	$	2,478,556
Hardware		24,781		-		47,008		900		72,689
Services		263,858		23,787		239,927		4,950		532,522
Total Revenues	$	697,169	$	576,417	$	1,733,681	$	76,500	$	3,083,767

	North America		Africa		EMESA*		Asia		March 31, 2022
License fees	$	473,070	$	517,161	$	390,277	$	79,675	$	1,460,183
Hardware		71,900		12,033		1,251		-		85,184
Services		355,632		15,275		24,844		53		395,804
Total Revenues	$	900,602	$	544,469	$	416,372	$	79,728	$	1,941,171

*EMESA – Europe, Middle East, South America

Deferred Revenue 

Deferred revenue includes customer advances and amounts that have been paid by customer for which the contractual maintenance terms have not yet occurred. The majority of these amounts are related to maintenance contracts for which the revenue is recognized ratably over the applicable term, which generally is 12-60 months. Contracts greater than 12 months are segregated as long term deferred revenue. Maintenance contracts include provisions for unspecified when-and-if available product updates and customer telephone support services. At March 31, 2023 and December 31, 2022, amounts in deferred revenue were approximately $693,000 and $515,000, respectively. Revenue recognized during the three months ended March 31, 2023 and 2022 from amounts included in deferred revenue at the beginning of the period was approximately $223,000 and $234,000, respectively. The Company did not recognize any revenue from performance obligations satisfied in prior periods.

XML

Note 4 - Accounts Receivable

3 Months Ended

Mar. 31, 2023

Notes to Financial Statements

Loans, Notes, Trade and Other Receivables Disclosure [Text Block]

4. ACCOUNTS RECEIVABLE

Accounts receivable are carried at original amount less an estimate made for credit losses based on a review of all outstanding amounts on a monthly basis. Management determines the allowance for credit losses by regularly evaluating individual customer receivables and considering a customer’s financial condition, credit history, current economic conditions and other relevant factors, including specific reserves for certain accounts. Accounts receivable are written off when deemed uncollectible.

Accounts receivable at March 31, 2023 and December 31, 2022 consisted of the following:

	March 31,			December 31,
	2023			2022
Accounts receivable	$	3,985,988		$	2,096,569
Allowance for credit losses		(623,785	)		(573,785	)
Accounts receivable, net of allowance for credit losses	$	3,362,203		$	1,522,784

Bad debt expenses (if any) are recorded in selling, general, and administrative expense.

XML

Note 5 - Share Based Compensation

3 Months Ended

Mar. 31, 2023

Notes to Financial Statements

Share-Based Payment Arrangement [Text Block]

5. SHARE BASED COMPENSATION

The following table presents share-based compensation expenses for continuing operations included in the Company’s unaudited condensed consolidated statements of operations:

	Three Months Ended March 31,
	2023		2022
Selling, general and administrative	$	55,453	$	92,426
Research, development and engineering		15,922		17,271
	$	71,375	$	109,697

XML

Note 6 - Inventory

3 Months Ended

Mar. 31, 2023

Notes to Financial Statements

Inventory Disclosure [Text Block]

6. INVENTORY

Inventory is stated at the lower of cost, determined on a first in, first out basis, or realizable value. The Company periodically evaluates inventory items and establishes reserves for obsolescence accordingly. The Company also reserves for excess quantities, slow moving goods, and for other impairment of value based upon assumptions of future demand and market conditions. The $400,000 reserve on inventory is due to slow moving inventory purchased for projects in Nigeria. The Company is looking into other markets and opportunities to sell or return the product. Inventory is comprised of the following as of:

	March 31,			December 31,
	2023			2022
Finished goods	$	4,758,089		$	4,764,643
Fabricated assemblies		69,726			69,726
Reserve on finished goods		(400,000	)		(400,000	)
Total inventory	$	4,427,815		$	4,434,369

XML

Note 7 - Commitments and Contingencies

3 Months Ended

Mar. 31, 2023

Notes to Financial Statements

Commitments Disclosure [Text Block]

7. COMMITMENTS AND CONTINGENCIES

Distribution Agreement

Swivel Secure has a distribution agreement with Swivel Secure Limited (“SSL”). Terms of the agreement include the following:

1. The initial term of the agreement ends on January 31, 2027 and will be automatically extended for additional one-year terms thereafter unless either party provides written notice to the other party not later than 30 days before the end of the term that it does not wish to extend the term.

2. SSL appoints Swivel Secure as the exclusive distributor of SSL’s products, to market, sell and distribute in the EMEA (Europe, Middle East and Africa), excluding the United Kingdom and Republic of Ireland, for a defined discount on the sale price.

3. Swivel Secure is expected to generate a certain minimum level of orders of SSL products each year during the term of the agreement. If Swivel Secure fails to meet such minimum level of orders in any year, the exclusive distribution rights will terminate and Swivel Secure will serve as a non-exclusive distributer of SSL Products.

The Company expects the revenue targets to continue to be met based on historical performance and increasing distribution by Swivel Secure.

Litigation

From time to time, the Company may be involved in litigation relating to claims arising out of our operations in the normal course of business. As of March 31, 2023, the Company was not a party to any pending lawsuits.

XML

Note 8 - Leases

3 Months Ended

Mar. 31, 2023

Notes to Financial Statements

Lessee, Operating Leases [Text Block]

8. LEASES

The Company’s leases office space in New Jersey, Minnesota, New Hampshire, Madrid and Hong-Kong with lease termination dates in 2023 and 2024. The property leased in China is paid monthly as used, without a formal agreement. The following tables present the components of lease expense and supplemental balance sheet information related to the operating leases were:

	3 Months ended March 31, 2023		3 Months ended March 31, 2022
Lease cost
Total lease cost	$	63,139	$	55,219

Balance sheet information	March 31, 2023			December 31, 2022
Operating right-of-use assets	$	131,223		$	197,355
Operating lease liabilities, current portion	$	96,584		$	159,665
Operating lease liabilities, non-current portion		33,366			37,829
Total operating lease liabilities	$	129,950		$	197,494
Weighted average remaining lease term (in years) – operating leases		0.66			0.96
Weighted average discount rate – operating leases		5.50	%		5.50	%
Supplemental cash flow information related to leases were as follows:
Cash paid for amounts included in the measurement of operating lease liabilities for the three months ended March 31, 2023 and 2022:	$	69,821		$	65,108
Maturities of operating lease liabilities were as follows as of March 31, 2023:
2023 (9 months remaining)	$	95,911
2024		38,808
Total future lease payments	$	134,719
Less: imputed interest		(4,769	)
Total	$	129,950

XML

Note 9 - Convertible Note Payable

3 Months Ended

Mar. 31, 2023

Notes to Financial Statements

Debt Disclosure [Text Block]

9. CONVERTIBLE NOTE PAYABLE

Securities Purchase Agreement dated December 22, 2022

On December 22, 2022, the Company entered into and closed a securities purchase agreement (the “Purchase Agreement”) which issued a $2,200,000 principal amount senior secured promissory note (the “Note”). At closing, a total of $2,002,000 was funded, with the proceeds to be used for general working capital.

The principal amount of the Note is due six months following the date of issuance, subject to one six-month extension by the Company. Interest under the Note accrues at a rate of 10% per annum, payable monthly through month six. In the event the maturity date of the Note is extended, interest will accrue at the rate of 12% per annum in months seven through twelve, payable monthly. The Note is secured by a lien on substantially all of the Company’s assets and properties can be prepaid in whole or in part without penalty at any time.

In connection with the issuance of the Note, the Company issued to the investor 700,000 shares of Common Stock (the “Commitment Shares”) valued at $1.00 per share and a warrant (the “Warrant”) to purchase 200,000 shares of common stock (the “Warrant Shares”) at an exercise price of $3.00 per share, exercisable commencing on the date of issuance with a term of five years. In the event the Note is paid in full within six months after the date of issuance, the Company will exercise its right to repurchase 350,000 of the Commitment Shares for aggregate payment to the Investor of $1.00.

Upon issuance, the Note is not convertible into common stock or any other securities of the Company. Only after a date that is six (6) months following the issuance date of the Note and upon the occurrence of any events of default (as defined) and expiration of any applicable cure periods, all amounts due under the Note will immediately and automatically become due and payable in full, interest will accrue at the higher of 18% per annum or the maximum amount permitted by applicable law, the outstanding principal amount due under the Note will be increased by 30%, and the Investor will have the right to convert all amounts due under the Note into shares of common stock (the “Conversion Shares”) at a conversion price equal to the 10 day volume weighted average sales price of the Company’s common stock on the date of conversion, subject to the Share Cap described in the paragraph below.

The aggregate number of shares of common stock issuable in the forgoing transaction consisting of the Commitment Shares, the Warrant Shares, and the Conversion Shares are capped at 1,684,576 which is 19.9% of the Company’s issued and outstanding shares of common stock on December 22, 2022, the date the definitive transaction documents were executed (the “Share Cap”).

The Company elected the fair value measurement option for the Note as the Note had embedded derivatives that required bifurcation, and recorded the entire hybrid financing instrument at fair value under the guidance of ASC 825, Financial Instruments. As a result, the Note was recorded at fair value upon issuance and is subsequently remeasured at each reporting date until settled or converted. The Company reports interest expense, including accrued interest, related to the Note under the fair value option, separately from within the change in fair value of the Note in the accompanying consolidated statement of operations. See Note 13.

As of March 31, 2023 and December 31, 2022, the Note with principal balance of $2,200,000, at fair value, was recorded at $2,454,212 and $2,596,203, respectively.

XML

Note 10 - Earnings Per Share (EPS)

3 Months Ended

Mar. 31, 2023

Notes to Financial Statements

Earnings Per Share [Text Block]

10. EARNINGS PER SHARE (“EPS”)

The Company’s basic EPS is calculated using net income (loss) available to common shareholders and the weighted-average number of shares outstanding during the reporting period. Diluted EPS includes the effect from potential issuance of common stock, such as stock issuable pursuant to the exercise of stock options and warrants and the assumed conversion of preferred stock.

The following table sets forth options and warrants which were excluded from the diluted per share calculation because the exercise price was greater than the average market price of the common shares:

	Three Months Ended March 31,
	2023		2022
Stock options		202,996		212,461
Warrants		4,872,025		4,689,387
Total		5,075,021		4,901,848

XML

Note 11 - Stockholders' Equity

3 Months Ended

Mar. 31, 2023

Notes to Financial Statements

Equity [Text Block]

11. STOCKHOLDERS’ EQUITY

Issuances of Common Stock

During the three-month periods ended March 31, 2023, there have not been any shares of common stock issued to anyone outside the Company, except as noted below under Issuances to Directors, Executive Officers & Consultants

On March 8, 2022, the Company issued 269,060 shares of common stock of which 89,687 shares were held back by the Company to secure certain indemnification obligations under the Swivel Secure stock purchase agreement. The shares of Company common stock were issued at a total cost of $600,004, priced at $2.23, based on the contractual 20 day volume-weighted average price of the Company’s common stock immediately prior to the payment date as reported on the Nasdaq Capital Market

Issuances of Restricted Stock

Restricted stock consists of shares of common stock that are subject to restrictions on transfer and risk of forfeiture until the fulfillment of specified conditions. The fair value of nonvested shares is determined based on the market price of the Company's common stock on the grant date. Restricted stock is expensed ratably over the term of the restriction period.

During the three-month periods ended March 31, 2023 and 2022, the Company issued 40,000 and 274,250 shares of restricted common stock to certain employees and the board, respectively. These shares vest in equal annual installments over a three-year period from the date of grant and had a fair value on the date of issuance of $31,200 and $589,638, respectively.

Restricted stock compensation for the three-month period ended March 31, 2023 and 2022 was $59,056 and $39,840, respectively.

Issuances to Directors, Executive Officers & Consultants

During the three-month periods ended March 31, 2023 and 2022 the Company issued 15,388 and 9,382 shares of common stock to its directors in lieu of payment of board and committee fees valued at $12,002 and $20,020, respectively.

Employees’ exercise options

During the three-month periods ended March 31, 2023 and 2022, no employee stock options were exercised.

3. Warrants

There were no warrants issued during the three-month periods ended March 31, 2023 and 2022.

XML

Note 12 - Fair Values of Financial Instruments

3 Months Ended

Mar. 31, 2023

Notes to Financial Statements

Fair Value Disclosures [Text Block]

12. FAIR VALUES OF FINANCIAL INSTRUMENTS

Cash and cash equivalents, accounts receivable, due from factor, accounts payable and accrued liabilities are carried at, or approximate, fair value because of their short-term nature. The carrying value of the Company’s notes and loan payables approximated fair value as the interest rates related to the financial instruments approximated market.

XML

Note 13 - Fair Value Measurement of Convertible Note Payable

3 Months Ended

Mar. 31, 2023

Notes to Financial Statements

Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]

13. FAIR VALUE MEASUREMENT OF CONVERTIBLE NOTE PAYABLE

Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical unrestricted assets or liabilities;

Level 2: Quoted prices in markets that are not active or inputs which are observable either directly or indirectly for substantially the full term of the asset or liability; and

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity).

The following tables summarize the Note measured at fair value at March 31, 2023 and December 31, 2022:

March 31, 2023	Total		Level 1		Level 2		Level 3
Convertible note at fair value	$	2,454,212	$	-	$	-	$	2,454,212

December 31, 2022	Total		Level 1		Level 2		Level 3
Convertible note at fair value	$	2,596,203	$	-	$	-	$	2,596,203

The Company estimated the fair value of the convertible note using a probability-weighted discounted cash flow model with the following assumptions and significant terms of the convertible note at both March 31, 2023 and December 31, 2022:

1. Face amount - $2,200,000

2. Nominal interest rate – 10% - 12%

3. Default interest rate – 18%

4. Increase in principal upon a default – 30%

5. Present value discount rate – 15.04% at March 31, 2023 and 15.18% at December 31, 2022

6. Likelihood of default – estimated to be 50% at the extended maturity date

The following table shows the changes in fair value measurements for the convertible note using significant unobservable inputs (Level 3) during the three months ended March 31, 2023:

Beginning balance	$	2,596,203
Purchases and issuances		-
Change in fair value		(141,991	)
Ending balance	$	2,454,212

XML

Note 14 - Major Customers and Accounts Receivable

3 Months Ended

Mar. 31, 2023

Notes to Financial Statements

Concentration Risk Disclosure [Text Block]

14. MAJOR CUSTOMERS AND ACCOUNTS RECEIVABLE

For the three month periods ended March 31, 2023 and 2022, two customers accounted for 48% and one customer accounted for 27% of revenues, respectively. Two customers accounted for 45% of current accounts receivable as of March 31, 2023. At December 31, 2022, one customers accounted for 35% of current accounts receivable.

XML

Note 15 - Income Taxes

3 Months Ended

Mar. 31, 2023

Notes to Financial Statements

Income Tax Disclosure [Text Block]

15. INCOME TAXES

The Company recorded no income tax expense for the three months ended March 31, 2023 and 2022 because the estimated annual effective tax rate was zero. In determining the estimated annual effective income tax rate, the Company analyses various factors, including projections of the Company’s annual earnings and taxing jurisdictions in which the earnings will be generated, the impact of state and local income taxes, the ability to use tax credits and net operating loss carry forwards, and available tax planning alternatives.

As of March 31, 2023 and December 31, 2022, the Company provided a full valuation allowance against its net deferred tax assets since the Company believes it is more likely than not that its deferred tax assets will not be realized.

XML

Note 14 - Subsequent Events

3 Months Ended

Mar. 31, 2023

Notes to Financial Statements

Subsequent Events [Text Block]

16. SUBSEQUENT EVENTS

On May 5, 2023, the Company issued 2,858 shares of common stock to its directors in payment of board committee fees.

On May 5, 2023, 14,375 shares of restricted common stock were cancelled as a result of employees leaving the Company before the vesting period was completed.

On May 11, 2023, the Company issued 17,392 shares of common stock to its directors in payment of board fees.

On May 11, 2023, the Company issued 2,900 shares of common stock to its directors in payment of board committee fees.

XML

Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2023

Accounting Policies [Abstract]

Basis of Accounting, Policy [Policy Text Block]

Basis of Presentation

The accompanying unaudited interim condensed consolidated financial statements include the accounts of BIO-key International, Inc. and its wholly-owned subsidiaries (collectively, the “Company” or “BIO-key”) and are stated in conformity with accounting principles generally accepted in the United States of America (“GAAP”), pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). The operating results for interim periods are not necessarily indicative of results that may be expected for any other interim period or for the full year. Pursuant to such rules and regulations, certain financial information and footnote disclosures normally included in the financial statements have been condensed or omitted. Intercompany accounts and transactions have been eliminated in consolidation.

In the opinion of management, the accompanying unaudited interim consolidated financial statements contain all necessary adjustments, consisting only of those of a recurring nature, and disclosures to present fairly the Company’s financial position and the results of its operations and cash flows for the periods presented. The balance sheet at December 31, 2022 was derived from the audited financial statements, but does not include all of the disclosures required by GAAP. These unaudited interim condensed consolidated financial statements should be read in conjunction with the financial statements and the related notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the SEC on June 1, 2023.

Foreign Currency Transactions and Translations Policy [Policy Text Block]

Foreign Currencies

The Company accounts for foreign currency transactions pursuant to ASC 830, Foreign Currency Matters ("ASC 830”). The functional currency of the Company is the U.S. dollar, which is the currency of the primary economic environment in which it operates. In accordance with ASC 830, all assets and liabilities are translated into U. S. dollars using the current exchange rate at the end of each fiscal period. Revenues and expenses are translated using the average exchange rates prevailing throughout the respective periods. All transaction gains and losses from the measurement of monetary balance sheet items denominated in Euros are reflected in the statement of operations as appropriate. Translation adjustments are included in accumulated other comprehensive income (loss).

New Accounting Pronouncements, Policy [Policy Text Block]

Recently Issued Accounting Pronouncements

Effective January 1, 2023, the Company adopted ASU 2016-13, Financial Instruments-Credit Losses (Topic 326), referred to herein as ASU 2016-13, which significantly changes how entities will account for credit losses for most financial assets and certain other instruments that are not measured at fair value through net income. ASU 2016-13 replaces the existing incurred loss model with an expected credit loss model that requires entities to estimate an expected lifetime credit loss on most financial assets and certain other instruments. Under ASU 2016-13 credit impairment is recognized as an allowance for credit losses, rather than as a direct write-down of the amortized cost basis of a financial asset. The impairment allowance is a valuation account deducted from the amortized cost basis of financial assets to present the net amount expected to be collected on the financial asset. Once the new pronouncement is adopted by the Company, the allowance for credit losses must be adjusted for management’s current estimate at each reporting date. The new guidance provides no threshold for recognition of impairment allowance. Therefore, entities must also measure expected credit losses on assets that have a low risk of loss. For instance, trade receivables that are either current or not yet due may not require an allowance reserve under currently generally accepted accounting principles, but under the new standard, the Company will have to estimate an allowance for expected credit losses on trade receivables under ASU 2016-13. The adoption of ASU 2016-13 did not have a material effect on the consolidated financial statements of the Company. 

In August 2020, the Financial Accounting Standards Board issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40) (“ASU 2020-06”) to simplify accounting for certain financial instruments. ASU 2020-06 eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity’s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity’s own equity. ASU 2020-06 amends the diluted earnings per share guidance, including the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective for the Company on January 1, 2024 and should be applied on a full or modified retrospective basis. The Company is currently assessing the impact ASU 2020-06 will have on its consolidated financial statements.

Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying consolidated financial statements.

XML

Note 3 - Revenue From Contracts With Customers (Tables)

3 Months Ended

Mar. 31, 2023

Notes Tables

Disaggregation of Revenue [Table Text Block]

	North America		Africa		EMESA*		Asia		March 31, 2023
License fees	$	408,530	$	552,630	$	1,446,746	$	70,650	$	2,478,556
Hardware		24,781		-		47,008		900		72,689
Services		263,858		23,787		239,927		4,950		532,522
Total Revenues	$	697,169	$	576,417	$	1,733,681	$	76,500	$	3,083,767

	North America		Africa		EMESA*		Asia		March 31, 2022
License fees	$	473,070	$	517,161	$	390,277	$	79,675	$	1,460,183
Hardware		71,900		12,033		1,251		-		85,184
Services		355,632		15,275		24,844		53		395,804
Total Revenues	$	900,602	$	544,469	$	416,372	$	79,728	$	1,941,171

XML

Note 4 - Accounts Receivable (Tables)

3 Months Ended

Mar. 31, 2023

Notes Tables

Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]

	March 31,			December 31,
	2023			2022
Accounts receivable	$	3,985,988		$	2,096,569
Allowance for credit losses		(623,785	)		(573,785	)
Accounts receivable, net of allowance for credit losses	$	3,362,203		$	1,522,784

XML

Note 5 - Share Based Compensation (Tables)

3 Months Ended

Mar. 31, 2023

Notes Tables

Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]

	Three Months Ended March 31,
	2023		2022
Selling, general and administrative	$	55,453	$	92,426
Research, development and engineering		15,922		17,271
	$	71,375	$	109,697

XML

Note 6 - Inventory (Tables)

3 Months Ended

Mar. 31, 2023

Notes Tables

Schedule of Inventory, Current [Table Text Block]

	March 31,			December 31,
	2023			2022
Finished goods	$	4,758,089		$	4,764,643
Fabricated assemblies		69,726			69,726
Reserve on finished goods		(400,000	)		(400,000	)
Total inventory	$	4,427,815		$	4,434,369

XML

Note 8 - Leases (Tables)

3 Months Ended

Mar. 31, 2023

Notes Tables

Lessee, Operating Lease, Costs, Assets and Liabilities [Table Text Block]

	3 Months ended March 31, 2023		3 Months ended March 31, 2022
Lease cost
Total lease cost	$	63,139	$	55,219

Balance sheet information	March 31, 2023			December 31, 2022
Operating right-of-use assets	$	131,223		$	197,355
Operating lease liabilities, current portion	$	96,584		$	159,665
Operating lease liabilities, non-current portion		33,366			37,829
Total operating lease liabilities	$	129,950		$	197,494
Weighted average remaining lease term (in years) – operating leases		0.66			0.96
Weighted average discount rate – operating leases		5.50	%		5.50	%
Supplemental cash flow information related to leases were as follows:
Cash paid for amounts included in the measurement of operating lease liabilities for the three months ended March 31, 2023 and 2022:	$	69,821		$	65,108
Maturities of operating lease liabilities were as follows as of March 31, 2023:
2023 (9 months remaining)	$	95,911
2024		38,808
Total future lease payments	$	134,719
Less: imputed interest		(4,769	)
Total	$	129,950

XML

Note 10 - Earnings Per Share (EPS) (Tables)

3 Months Ended

Mar. 31, 2023

Notes Tables

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

	Three Months Ended March 31,
	2023		2022
Stock options		202,996		212,461
Warrants		4,872,025		4,689,387
Total		5,075,021		4,901,848

XML

Note 13 - Fair Value Measurement of Convertible Note Payable (Tables)

3 Months Ended

Mar. 31, 2023

Notes Tables

Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]

March 31, 2023	Total		Level 1		Level 2		Level 3
Convertible note at fair value	$	2,454,212	$	-	$	-	$	2,454,212

December 31, 2022	Total		Level 1		Level 2		Level 3
Convertible note at fair value	$	2,596,203	$	-	$	-	$	2,596,203

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

Beginning balance	$	2,596,203
Purchases and issuances		-
Change in fair value		(141,991	)
Ending balance	$	2,454,212

XML

Note 3 - Revenue From Contracts With Customers (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Contract with Customer, Liability	$ 693,000		$ 515,000
Contract with Customer, Liability, Revenue Recognized	$ 223,000	$ 234,000

XML

Note 3 - Revenue From Contracts With Customers - Disaggregation of Revenue (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Total revenues	$ 3,083,767	$ 1,941,171
North America [Member]
Total revenues	697,169	900,602
Africa [Member]
Total revenues	576,417	544,469
EMEA [Member]
Total revenues	1,733,681	416,372
Asia [Member]
Total revenues	76,500	79,728
License [Member]
Total revenues	2,478,556	1,460,183
License [Member] | North America [Member]
Total revenues	408,530	473,070
License [Member] | Africa [Member]
Total revenues	552,630	517,161
License [Member] | EMEA [Member]
Total revenues	1,446,746	390,277
License [Member] | Asia [Member]
Total revenues	70,650	79,675
Hardware [Member]
Total revenues	72,689	85,184
Hardware [Member] | North America [Member]
Total revenues	24,781	71,900
Hardware [Member] | Africa [Member]
Total revenues	0	12,033
Hardware [Member] | EMEA [Member]
Total revenues	47,008	1,251
Hardware [Member] | Asia [Member]
Total revenues	900	0
Service [Member]
Total revenues	532,522	395,804
Service [Member] | North America [Member]
Total revenues	263,858	355,632
Service [Member] | Africa [Member]
Total revenues	23,787	15,275
Service [Member] | EMEA [Member]
Total revenues	239,927	24,844
Service [Member] | Asia [Member]
Total revenues	$ 4,950	$ 53

XML

Note 4 - Accounts Receivable - Summary of Accounts Receivable (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Accounts receivable	$ 3,985,988	$ 2,096,569
Allowance for doubtful accounts	(623,785)	(573,785)
Accounts receivable, net of allowances for doubtful accounts	$ 3,362,203	$ 1,522,784

XML

Note 5 - Share Based Compensation - Expenses for Continuing Operations (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Share-based compensation expense	$ 71,375	$ 109,697
Selling, General and Administrative Expenses [Member]
Share-based compensation expense	55,453	92,426
Research and Development Expense [Member]
Share-based compensation expense	$ 15,922	$ 17,271

XML

Note 6 - Inventory (Details Textual)	Mar. 31, 2023 USD ($)
NIGERIA
Inventory Valuation Reserves	$ 400,000

XML

Note 6 - Inventory - Components of Inventory (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Finished goods	$ 4,758,089	$ 4,764,643
Fabricated assemblies	69,726	69,726
Reserve on finished goods	(400,000)	(400,000)
Total inventory	$ 4,427,815	$ 4,434,369

XML

Note 8 - Leases - Operating Lease Balance Sheet Information (Details) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Total lease cost	$ 63,139	$ 55,219
Operating lease right-of-use assets	131,223		$ 197,355
Operating lease liabilities, current portion	96,584		159,665
Operating lease liabilities, non-current portion	33,366		37,829
Total operating lease liabilities	$ 129,950		$ 197,494
Weighted average remaining lease term (in years) – operating leases (Year)	7 months 28 days		11 months 15 days
Weighted average discount rate – operating leases	5.50%		5.50%
Cash paid for amounts included in the measurement of operating lease liabilities	$ 69,821		$ 65,108
2023 (9 months remaining)	95,911
Lessee, Operating Lease, Liability, to be Paid, Year One	38,808
Total future lease payments	134,719
Less: imputed interest	(4,769)
Total	$ 129,950		$ 197,494

XML

Note 9 - Convertible Note Payable (Details Textual) - USD ($)	Dec. 22, 2022	Jun. 23, 2023	Mar. 31, 2023	Dec. 31, 2022
Warrants Issued in Connection With Note [Member]
Class of Warrant or Right, Issued During Period	200,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 3.00
The Note [Member]
Debt Instrument, Face Amount			$ 2,200,000	$ 2,200,000
Debt Instrument, Fair Value Disclosure			$ 2,454,212	$ 2,596,203
The Note [Member] | Senior Secured Promissory Note [Member]
Debt Instrument, Face Amount	$ 2,200,000
Proceeds from Debt, Net of Issuance Costs	$ 2,002,000
Debt Instrument, Interest Rate, Stated Percentage	10.00%
Stock Issued During Period, Shares, Commitment Fee	700,000
Shares Issued, Price Per Share	$ 1.00
Right to Repurchase Shares if Debt Instrument Paid in Full Within Six Months	350,000
Debt Instrument, Interest Rate, Default	18.00%
Debt Instrument, Default, Percentage Increase In Principal	30.00%
The Note [Member] | Senior Secured Promissory Note [Member] | Maximum [Member]
Debt Instrument, Convertible, Number of Equity Instruments	1,684,576
Debt Instrument, Convertible, Percentage of Outstanding Stock	19.90%
The Note [Member] | Senior Secured Promissory Note [Member] | Forecast [Member]
Debt Instrument, Interest Rate, Stated Percentage		12.00%

XML

Note 10 - Earnings Per Share (EPS) - Securities Excluded From the Diluted Per Share Calculation 2 (Details) - Exercise Price Greater Than Average Market Price Of Common Shares [Member] - shares	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Antidilutive securities (in shares)	5,075,021	4,901,848
Share-Based Payment Arrangement, Option [Member]
Antidilutive securities (in shares)	202,996	212,461
Warrant [Member]
Antidilutive securities (in shares)	4,872,025	4,689,387

XML

Note 11 - Stockholders' Equity (Details Textual) - USD ($)		3 Months Ended
	Mar. 08, 2022	Mar. 31, 2023	Mar. 31, 2022
Stock Issued During Period, Value, Acquisitions			$ 600,004
Share-Based Payment Arrangement, Expense		$ 71,375	109,697
Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture		$ 12,002	$ 22,020
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares)		0	0
Common Stock [Member]
Stock Issued During Period, Value, Acquisitions			$ 27
Stock Issued During Period, Shares, Restricted Stock Award, Forfeited		19,834
Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture		15,388	9,382
Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture		$ 1	$ 1
Common Stock [Member] | Director [Member]
Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture		15,388	9,382
Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture		$ 12,002	$ 20,020
Restricted Stock [Member]
Stock Issued During Period, Shares, Restricted Stock Award, Forfeited		40,000	274,250
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value		$ 31,200	$ 589,638
Share-Based Payment Arrangement, Expense		$ 59,056	$ 39,840
Swivel Secure Europe [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	269,060
Business Combination, Indemnification Assets, Amount as of Acquisition Date	$ 89,687
Stock Issued During Period, Value, Acquisitions	$ 600,004
Business Acquisition, Share Price	$ 2.23

XML

Note 13 - Fair Value Measurement of Convertible Note Payable (Details Textual) - The Note [Member] - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Debt Instrument, Face Amount	$ 2,200,000	$ 2,200,000
Senior Secured Convertible Note [Member]
Debt Instrument, Face Amount	$ 2,200,000	$ 2,200,000
Debt Instrument, Interest Rate, Default	18.00%	18.00%
Debt Instrument, Default, Percentage Increase In Principal	30.00%	30.00%
Debt Instrument, Likelihood of Default	50.00%	50.00%
Senior Secured Convertible Note [Member] | Measurement Input, Discount Rate [Member]
Debt Instrument, Measurement Input	0.1504	0.1518
Senior Secured Convertible Note [Member] | Minimum [Member]
Debt Instrument, Interest Rate, Stated Percentage	10.00%	10.00%
Senior Secured Convertible Note [Member] | Maximum [Member]
Debt Instrument, Interest Rate, Stated Percentage	12.00%	12.00%

XML

Note 13 - Fair Value Measurement of Convertable Note Payable - Fair Value Measured on Recurring and nonrecurring Basis (Details) - The Note [Member] - Senior Secured Convertible Note [Member] - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Convertible note at fair value	$ 2,454,212	$ 2,596,203
Fair Value, Inputs, Level 1 [Member]
Convertible note at fair value	0	0
Fair Value, Inputs, Level 2 [Member]
Convertible note at fair value	0	0
Fair Value, Inputs, Level 3 [Member]
Convertible note at fair value	$ 2,454,212	$ 2,596,203

XML

Note 13 - Fair Value Measurement of Convertable Note Payable - Unobsesrvable Input Reconciliation (Details) - The Note [Member] - Senior Secured Convertible Note [Member]	3 Months Ended
	Mar. 31, 2023 USD ($)
Beginning balance	$ 2,596,203
Purchases and issuances	0
Change in fair value	(141,991)
Ending balance	$ 2,454,212

XML

Note 14 - Major Customers and Accounts Receivable (Details Textual) - Customer Concentration Risk [Member]	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenue Benchmark [Member] | Two Customers [Member]
Concentration Risk, Percentage	48.00%
Revenue Benchmark [Member] | One Customer [Member]
Concentration Risk, Percentage		27.00%
Accounts Receivable [Member] | Two Customers [Member]
Concentration Risk, Percentage	45.00%
Accounts Receivable [Member] | One Customer [Member]
Concentration Risk, Percentage		35.00%

XML

Note 15 - Income Taxes (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Tax Expense (Benefit)	$ 0	$ 0

XML

Note 14 - Subsequent Events (Details Textual) - Forecast [Member] - shares	May 11, 2023	May 05, 2023
Restricted Stock [Member] | Share-Based Payment Arrangement, Employee [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period		14,375
Director [Member] | Common Stock [Member] | Stock Issued in Lieu of Board Committee Fees [Member]
Shares Issued, Shares, Share-Based Payment Arrangement, before Forfeiture	2,900	2,858
Director [Member] | Common Stock [Member] | Stock Issued in Lieu of Board Fees [Member]
Shares Issued, Shares, Share-Based Payment Arrangement, before Forfeiture	17,392